Table 2.
The ongoing clinical trials targeting on B7 family molecules.
| Targets | Drug | Disease | Phase | Status | Trial ID |
|---|---|---|---|---|---|
| PD-L1 | Durvalumab lenalidomide |
NKTCL | II | Not yet recruiting | NCT03054532 |
| PD-L1 | Durvalumab Rituximab Acalabrutinib |
PCNSL | I | Not yet recruiting | NCT04688151 |
| PD-L1 | Acalabrutinib Durvalumab |
PCNSL SCNSL |
I | Not yet recruiting | NCT04462328 |
| PD-L1 | Atezolizumab | DLBCL | Recruiting | NCT03850028 | |
| PD-L1 | Atezolizumab Rituximab Gemcitabine Oxaliplatin |
r/r DLBCL | II | Active, not recruiting | NCT03422523 |
| PD-L1 | Atezolizumab | CTCL,SS | II | Active, not recruiting | NCT03357224 |
| PD-L1 | Avelumab | r/r ENKTCL | II | Active, not recruiting | NCT03439501 |
| PD-L1 | Avelumab | Advanced HL | II | Recruiting | NCT03617666 |
| PD-L1 | Avelumab | PTCL | II | Active, not recruiting | NCT03046953 |
| B7-H3 | B7-H3 CAR T | DIPG, DMG, r/r CNS tumors | I | Recruiting | NCT04185038 |
| B7-H3 | B7-H3 CAR T | r/r Glioblastoma | II | Recruiting | NCT04077866 |
| B7-H3 | B7-H3 CAR T | r/r solid tumors | I | Recruiting | NCT04483778 |
| B7-H3 | 4SCAR-276 | solid tumors | I/II | Recruiting | NCT04432649 |
| B7-H3 | B7-H3 CAR T, Fludarabine, Cyclophosphamide | Epithelial Ovarian Cancer | I | Not recruiting | NCT04670068 |
| B7-H3 | MGA271 | Prostate Cancer | II | Active, not recruiting | NCT02923180 |
| B7-H3 | Enoblituzumab, Retifanlimab, Tebotelimab | Head and neck caner | II | Not recruiting | NCT04634825 |
| B7-H3 | MGC018 | Advanced solid tumors | I | Recruiting | NCT03729596 |
| B7-H3 | MGD009 | Advanced solid tumors | I | Active, not recruiting | NCT02923180 |
| B7-H4 | FPA150 | Advanced solid tumors | I | Active, not recruiting | NCT03406949 |
| B7-H6 | BI 765049 BI 754091 |
Advanced solid tumors | I | Not recruiting | NCT04752215 |
CNS, central nervous system; CTCL, cutaneous T‐cell lymphoma; DIPG, diffuse intrinsic pontine glioma; DMG, diffuse midline glioma; DLBCL, diffuse large B-cell lymphoma; ENKTCL, extranodal natural killer/T-cell lymphoma; HL, Hodgkin Lymphoma; PCNSL, primary central nervous system lymphoma; PTCL, Peripheral T-cell Lymphoma; r/r, relapsed or refractory; SCNSL, secondary central nervous system lymphoma; SS, Sezary syndrome.